Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

Mariano Provencio, Margarita Majem, M. Guirado, Bartomeu Massutí, Ramón de las Peñas, Ana Laura Ortega Granados, Manuel Dómine, Raquel Marsé, María Ángeles Sala, Alfredo Paredes, Teresa Morán, Sergio Vázquez‐Estévez, Juan Coves, J.L. González-Larriba, José Miguel Sánchez, David Vicente, Núria Farré, L. Fernández Fornos, I. Vicente Zapata, Fernando Franco, Roberto Serna‐Blasco, Atocha Romero, Dolores Isla